ALT5 Sigma Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor ALT5 Sigma te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.6%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

Mar 31

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Feb 14

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

Oct 03

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat ALT5 Sigma onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NasdaqCM:ALTS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/29/2024	2	-18	-1	-1	N/A
3/30/2024	N/A	-19	-2	-2	N/A
12/30/2023	N/A	-17	1	1	N/A
9/30/2023	40	0	0	2	N/A
7/1/2023	N/A	5	-1	-2	N/A
4/1/2023	N/A	5	-2	-2	N/A
12/31/2022	N/A	8	-3	-3	N/A
10/1/2022	11	2	-5	-5	N/A
7/2/2022	23	2	-3	-2	N/A
4/2/2022	31	-1	-5	-3	N/A
1/1/2022	40	-3	-7	-5	N/A
10/2/2021	39	-6	-5	-3	N/A
7/3/2021	39	-6	-4	-1	N/A
4/3/2021	34	-6	-3	-2	N/A
1/2/2021	34	-8	-1	-1	N/A
9/26/2020	36	-12	-1	-1	N/A
6/27/2020	34	-13	-4	-4	N/A
3/28/2020	37	-12	-3	-3	N/A
12/28/2019	35	-12	-4	-4	N/A
9/28/2019	33	-7	-3	-3	N/A
6/29/2019	33	-6	0	0	N/A
3/30/2019	34	-6	0	1	N/A
12/29/2018	37	-6	4	4	N/A
9/29/2018	39	-2	3	3	N/A
6/30/2018	41	0	1	1	N/A
3/31/2018	43	2	N/A	2	N/A
12/30/2017	42	6	N/A	1	N/A
9/30/2017	-7	5	N/A	0	N/A
7/1/2017	9	6	N/A	0	N/A
4/1/2017	23	3	N/A	2	N/A
12/31/2016	40	0	N/A	3	N/A
10/1/2016	103	-2	N/A	2	N/A
7/2/2016	104	-4	N/A	2	N/A
4/2/2016	110	-1	N/A	-2	N/A
1/2/2016	112	-3	N/A	-3	N/A
10/3/2015	118	-2	N/A	-2	N/A
7/4/2015	123	-1	N/A	2	N/A
4/4/2015	125	-2	N/A	2	N/A
1/3/2015	131	1	N/A	4	N/A
9/27/2014	131	2	N/A	1	N/A
6/28/2014	131	3	N/A	1	N/A
3/29/2014	131	4	N/A	0	N/A
12/28/2013	128	3	N/A	2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van ALTS boven de spaarquote ( 2.5% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van ALTS naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van ALTS naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van ALTS naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van ALTS naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ALTS naar verwachting over 3 jaar hoog zal zijn

ALT5 Sigma Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

ALT5 Sigma Corporation, Annual General Meeting, Dec 18, 2024

ALT5 Sigma Corporation Announces Chief Executive Officer Changes

ALT5 Sigma Corporation announced delayed 10-Q filing

Insufficient new directors

JanOne Regains Compliance with Nasdaq's Listing Rule 5550(b)(1)

JanOne Inc. (NasdaqCM:JAN) completed the acquisition of Alt 5 Sigma Inc.

JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

JanOne Inc. announced delayed annual 10-K filing

JanOne Regains Compliance with Nasdaq’s Listing Requirements

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 93%

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

New minor risk - Profit margin trend

New major risk - Shareholder dilution

New major risk - Share price stability

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

JanOne Receives Non-Compliance Notice from the Nasdaq Stock Market

JanOne Inc., Annual General Meeting, Oct 09, 2023

New minor risk - Share price stability

New major risk - Earnings quality

Janone Inc. Files International Patent Application for Methods of Using Low Dose Naltrexone to Treat Chronic Pain

JanOne Inc. announced delayed 10-Q filing

Full year 2022 earnings released: EPS: US$1.14 (vs US$6.35 loss in FY 2021)

JanOne Received A Notice from the NASDAQ Stock Market

Third quarter 2022 earnings released: US$0.66 loss per share (vs US$0.34 loss in 3Q 2021)

High number of new and inexperienced directors

JanOne Inc., Annual General Meeting, Nov 02, 2022

JanOne Inc. (NasdaqCM:JAN) enter into a term sheet to acquire Soin Therapeutics LLC Soin Therapeutics LLC for $30 million.

JanOne to acquire Soin Therapeutics

Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: EPS: US$3.39 (vs US$2.07 loss in 2Q 2021)

JanOne Inc. Announces an Improved Formulation of JAN101

JanOne Inc. Announces the Issuance of U.S. Patent Covering A Method of Improving Nerve Function Using Jan101

First quarter 2022 earnings released: EPS: US$0.43 (vs US$0.26 in 1Q 2021)

High number of new and inexperienced directors

JanOne Receives Notice from Nasdaq for Not Complying with Listing Rules

Full year 2021 earnings released: US$6.35 loss per share (vs US$4.59 loss in FY 2020)

Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?

Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.43 loss in 3Q 2020)

High number of new and inexperienced directors

Janone Janone Inc. Revises Its Development Strategy Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate Jan101

Janone Inc. Readies Clinical Supply of Lead Product Candidate Jan101 for Distribution to Phase 2B Trial Sites

JanOne Selects Regulatory Partner for Phase 2B Trial as Investigational Plan Is Prepared for FDA Filing

JanOne adds Nicholas Goeders to scientific advisory board

JanOne Announces Initiation of Phase 2b Peripheral Artery Disease Trial for Lead Product Candidate JAN101

JanOne advances toward initiation of mid-stage peripheral artery disease trial

Chief Financial Officer recently sold US$221k worth of stock

First quarter 2021 earnings released: EPS US$0.26 (vs US$1.33 loss in 1Q 2020)

Full year 2020 earnings released: US$4.59 loss per share (vs US$6.78 loss in FY 2019)

Virland Johnson entered into a definitive agreement to acquire substantially all assets and certain liabilities of ARCA Recycling, Inc. from JanOne Inc. (NasdaqCM:JAN) for $25 million.

JanOne Inc. has completed a Follow-on Equity Offering in the amount of $5.999994 million.

JanOne under pressure on pricing $6M stock offering

New 90-day high: US$5.47

New 90-day high: US$5.08

Third quarter 2020 earnings released: US$0.43 loss per share

New 90-day low: US$3.50

JanOne Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study

New 90-day high - US$5.86

Earnings released

New 90-day high - US$3.74

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven